Change in lymphocyte gene expression induced by Campath-1H treatment of multiple sclerosis
J.A. Somerfield, J.L. Jones, V.H. Robertson, D.A.S. Compston, A.J. Coles (Cambridge, UK)
Objectives: Campath-1H, a humanised monoclonal antibody to CD52, causes profound lymphopenia. It significantly reduces the relapse rate of multiple sclerosis and, intriguingly, results in reduced EDSS scores at 36months. This study aims to identify changes in peripheral lymphocyte gene expression associated with this improvement in disability after Campath-1H treatment.
Methods: Blood ...